British and Italian researchers have demostrated promising results in patients with progressive multiple sclerosis through stem cell transplantation into the brain.
French Sanofi SA’s second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements.
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.
Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.
Finnish protein maker Solar Foods has closed an oversubscribed €8M Series B financing and will expand Solein protein production and support the construction of a commercial production plant.
The Budget Committee of the German Bundestag has announced to channel €38m in funding into the sustainable protein transition next year.
German precision fermentation specialist MicroHarvest GmbH has launched a single-cell protein pilot plant in Lison with an initial capacity of 25kg per day.
The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing.
Dutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.
Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.